Welcome to our dedicated page for Optimizerx news (Ticker: OPRX), a resource for investors and traders seeking the latest updates and insights on Optimizerx stock.
OptimizeRx Corp (NASDAQ: OPRX) provides a dedicated news hub for tracking developments in healthcare technology and digital patient engagement solutions. This page aggregates official announcements, financial disclosures, and strategic updates from the leader in EHR-integrated pharma messaging.
Investors and industry professionals will find curated coverage of earnings reports, technology partnerships, product launches, and regulatory milestones. The resource serves as a centralized source for understanding OPRX's role in connecting pharmaceutical companies with healthcare providers through cloud-based communication platforms.
Key content categories include financial results, strategic alliances with EHR providers, technology innovations in digital health messaging, and industry recognition of platform advancements. All materials maintain factual accuracy and timeliness required for informed decision-making.
Bookmark this page for streamlined access to OptimizeRx's evolving position in medication adherence solutions and AI-driven healthcare communications. Regular updates ensure stakeholders stay informed about developments impacting the digital pharma marketing landscape.
OptimizeRx Corporation (Nasdaq: OPRX) will host a conference call on February 24, 2021, at 4:30 p.m. ET to discuss its fourth-quarter and full-year 2020 results. The company anticipates reporting record revenue exceeding $16 million, reflecting a 117% increase year-over-year, alongside positive GAAP net income. This growth is attributed to the expanded use of its digital health solutions by life science companies, boosting provider and patient engagement. Full financial results will be disclosed prior to the call.
OptimizeRx Corporation (Nasdaq: OPRX) has been invited to present at the SVB Leerink 10th Annual Global Healthcare Conference from February 22-26, 2021. CEO William Febbo is set to present on February 25 at 5:00 p.m. Eastern time, along with virtual meetings with analysts and investors. The firm reported record preliminary results for Q4 and full year 2020, expecting a 117% revenue increase to $16 million for Q4, and a 75% increase to $43 million for the full year. These gains reflect increased engagement among life science companies using OptimizeRx’s digital health network.
OptimizeRx Corporation (Nasdaq: OPRX) has priced an underwritten public offering of 1,325,000 shares at $49.50 each, aiming for gross proceeds of approximately $65.6 million. Underwriters hold a 30-day option for an additional 198,750 shares. Closing is expected around February 11, 2021. Proceeds will be used for general corporate purposes, potentially including future acquisitions, although no immediate agreements are in place. The offering is conducted under an effective shelf registration statement with the SEC, ensuring compliance and transparency for investors.
OptimizeRx Corporation (Nasdaq: OPRX) announced the commencement of an underwritten public offering of its common stock. The company may grant underwriters a 30-day option to purchase an additional 15% of the shares being offered. Proceeds from the offering will be utilized for general corporate purposes, potentially including future acquisitions. The offering is subject to market conditions, with no guarantees on completion or terms. A registration statement has been filed with the SEC and is effective as of February 8, 2021.
OptimizeRx Corp. (Nasdaq: OPRX) announced record preliminary financial results for the fourth quarter and full year ended December 31, 2020. The company expects fourth-quarter revenue to reach approximately $16 million, a 117% increase year-over-year, alongside positive GAAP net income. For the full year, revenue is projected at $43 million, up 75%. Strong growth is attributed to increased demand for digital health solutions from life science companies. OptimizeRx aims for continued expansion, reporting a robust sales pipeline of $170 million heading into 2021.
OptimizeRx Corp. (Nasdaq: OPRX), a leader in digital health solutions, announced its upcoming presentation at the B. Riley Securities 2021 Vision Day Conference on January 28, 2021, at 1:30 p.m. Eastern time. CEO William Febbo will discuss the company's expansive digital health platform, which connects life science companies with patients' care journeys, facilitating medication affordability and adherence. The event will feature a live webcast and is expected to address OptimizeRx's growth opportunities and new digital health solutions.
OptimizeRx Corp. (Nasdaq: OPRX) has been invited to present at the H.C. Wainwright BioConnect Conference, taking place virtually from January 11-14, 2021. The presentation will be available on-demand starting at 6:00 a.m. ET on January 11 and can be accessed via the conference portal and OptimizeRx’s investor relations page. CEO William Febbo will hold one-on-one virtual meetings with institutional analysts and investors, highlighting the company's expanding market due to new digital health solutions. OptimizeRx reported $34.3 million in trailing revenue for the 12 months ending September 30, 2020, marking a 44% increase from the previous year.
OptimizeRx Corp. (Nasdaq: OPRX) has been invited to the Bank of America 4th Annual HCIT and Digital Health Symposium on December 9-10, 2020. CEO William Febbo will speak on the panel discussing "Trends in Tech-Enabled Rx Supply Chain." The event will include healthcare-focused Bank of America clients and executives from various sectors, including digital health and private equity. OptimizeRx offers digital health solutions linking healthcare providers and patients, helping improve medication affordability and adherence.
OptimizeRx announces a partnership with Komodo Health to integrate its Healthcare Map with OptimizeRx's digital health platform. This collaboration aims to enhance real-world evidence delivery to healthcare providers, expanding OptimizeRx's audience and improving care through actionable insights. As the COVID-19 pandemic has changed care delivery, the partnership focuses on addressing gaps in timely information for healthcare providers. OptimizeRx aims to leverage this integration to bolster patient and physician experiences, ultimately improving treatment outcomes.
